Inactive Instrument

News Catabasis Pharmaceuticals Inc Nasdaq

Equities

US14875P1075

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 02	BU
HC Wainwright Cuts Astria Therapeutics' Price Target to $16 From $18, Maintains Buy Rating	Apr. 23	MT
Astria Therapeutics : - 2024 Proxy Statement	Apr. 22	PU
Astria Therapeutics : - 2023 Annual Report	Apr. 22	PU
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors	Apr. 09	BU
Astria Therapeutics, Inc. Appoints Sunil Agarwal to the Board of Directors and Member of the Science and Technology Committee	Apr. 09	CI
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	Apr. 04	AQ
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 03	BU
Wedbush Raises Astria Therapeutics' PT to $22 From $17 After Reporting Top-Line Phase 1/2 ALPHA-STAR Results for STAR-0215 Program; Maintains Outperform Rating	Mar. 26	MT
Transcript : Astria Therapeutics, Inc. - Special Call	Mar. 25
Astria Therapeutics : Material Event - Form 8-K	Mar. 25	PU
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE	Mar. 25	BU
Astria Therapeutics, Inc. Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE	Mar. 25	CI
North American Morning Briefing : Markets on Hold -2-	Mar. 20	DJ
Astria Therapeutics, Inc.(NasdaqGM:ATXS) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
Certain Stock Options of Astria Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2024.	Mar. 15	CI
Certain Common Stock of Astria Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2024.	Mar. 15	CI
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	Mar. 06	AQ
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 05	BU
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update	Mar. 04	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Catabasis Pharmaceuticals Inc Nasdaq

Equities

US14875P1075

Summary

Filters